Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A pregnant woman who has either a positive blood smear for P.falciparum with at least 1000 asexual parasites/uL in an asymptomatic woman~or any of the following symptoms within 2 days prior to consultation:~* history of fever;~* headache,~* vomiting,~* chills/rigors,~* and/or any of the following signs: temperature \>37.50C and \<39.50C, Hb\>5 and \<9 g/dl together with P.falciparum parasitaemia at any density~and (in both cases) the following:~1. Has no exclusion criterion (see below);~2. Is 14-34 weeks pregnant on the day of attending the ANC clinic or OPD;~3. Has a viable foetus, defined by presence of foetal heartbeat by sonicaid or pinnard (foetal heartbeat is not heard until 14 weeks);~4. Is able to take study drugs by the oral route;~5. Is able to attend stipulated days for follow up clinic and provide specimens;~6. Gives informed written or witnessed verbal consent to participate by herself, and also through her parent/guardian if aged \<15 years (in conformity to Tanzania Law).~Exclusion Criteria:~1. Severe and complicated forms of malaria (as defined by WHO, 1996);~2. Pregnancy in the first trimester;~3. A mixed plasmodial infection;~4. Complicated pregnancy, e.g. signs/symptoms of toxaemia of pregnancy;~5. 23 or more abortions or stillbirths;~6. Presence of concomitant disease masking assessment of the response to treatment ;~7. An intake of drugs contraindicated in pregnancy, e.g. tetracycline, cotrimoxazole or a macrolide antibiotic;~8. An intake of drugs with effective antimalarial activity within the last 2 weeks.~9. Significantly abnormal baseline haematology (except anaemia) or clinical chemistry parameters, e.g. laboratory evidence of renal impairment (serum creatinine \>2 mg/dl) or of hepatitis (alanine aminotransferase \[ALT\] \>5 times upper limit of normal);~10. Previous participation in the study: Women having a second episode of malaria after completing the 28-day follow up will have details recorded and offered quinine but not be re-enrolled.~11. Multiple gestation pregnancies, eg twins~12. Mother aged 38 years or above

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).